Mark Lazarus

2.2k total citations · 1 hit paper
8 papers, 1.8k citations indexed

About

Mark Lazarus is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Mark Lazarus has authored 8 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Immunology. Recurrent topics in Mark Lazarus's work include Systemic Lupus Erythematosus Research (4 papers), T-cell and B-cell Immunology (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Mark Lazarus is often cited by papers focused on Systemic Lupus Erythematosus Research (4 papers), T-cell and B-cell Immunology (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). Mark Lazarus collaborates with scholars based in United Kingdom, United States and Sweden. Mark Lazarus's co-authors include David M. Turner, Ian V. Hutchinson, P. J. Sinnott, David Sankaran, Denise Williams, Paul J. Sinnott, Jane Worthington, William Ollier, Ali H. Hajeer and Michael R. Ehrenstein and has published in prestigious journals such as Annals of the Rheumatic Diseases, European Journal of Immunology and Lara D. Veeken.

In The Last Decade

Mark Lazarus

8 papers receiving 1.8k citations

Hit Papers

AN INVESTIGATION OF POLYM... 1997 2026 2006 2016 1997 400 800 1.2k

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark Lazarus 988 438 359 239 196 8 1.8k
Jeff L. Bidwell 780 0.8× 351 0.8× 268 0.7× 264 1.1× 181 0.9× 19 1.7k
Leigh Keen 892 0.9× 361 0.8× 205 0.6× 285 1.2× 251 1.3× 42 1.9k
David Sankaran 1.1k 1.1× 494 1.1× 225 0.6× 250 1.0× 373 1.9× 10 2.1k
David Senitzer 1.1k 1.1× 433 1.0× 293 0.8× 295 1.2× 149 0.8× 115 2.3k
Alain Chevailler 841 0.9× 685 1.6× 269 0.7× 176 0.7× 156 0.8× 87 2.2k
Chris Perrey 937 0.9× 572 1.3× 162 0.5× 289 1.2× 352 1.8× 18 2.0k
Y Niho 879 0.9× 261 0.6× 351 1.0× 315 1.3× 178 0.9× 74 2.1k
Stina Salomonsson 634 0.6× 329 0.8× 545 1.5× 151 0.6× 220 1.1× 58 1.7k
Claire Galambrun 494 0.5× 253 0.6× 222 0.6× 395 1.7× 151 0.8× 79 2.5k
Estela Paz‐Artal 1.1k 1.1× 371 0.8× 336 0.9× 192 0.8× 370 1.9× 96 2.1k

Countries citing papers authored by Mark Lazarus

Since Specialization
Citations

This map shows the geographic impact of Mark Lazarus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lazarus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lazarus more than expected).

Fields of papers citing papers by Mark Lazarus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lazarus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lazarus. The network helps show where Mark Lazarus may publish in the future.

Co-authorship network of co-authors of Mark Lazarus

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lazarus. A scholar is included among the top collaborators of Mark Lazarus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lazarus. Mark Lazarus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Baker, Tina, Paul J. Newcombe, Patrick G. Gavin, et al.. (2024). Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials. Annals of the Rheumatic Diseases. 83(8). 1018–1027. 32 indexed citations
2.
Jayne, David, Patrick J. Gavin, Erik L. Allman, et al.. (2023). OP0136 METABOLOMIC SERUM PROFILING IDENTIFIES METABOLITES LINKED TO KIDNEY DAMAGE WHICH ARE MODULATED BY ANIFROLUMAB IN A PHASE 2 TRIAL IN LUPUS NEPHRITIS. Annals of the Rheumatic Diseases. 82. 90–90. 2 indexed citations
4.
Lazarus, Mark, Tabitha Turner‐Stokes, Konstantia-Maria Chavele, David Isenberg, & Michael R. Ehrenstein. (2012). B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. Lara D. Veeken. 51(7). 1208–1215. 57 indexed citations
5.
Lazarus, Mark & Howard L. Kaufman. (2011). An association between corticosteroid use and melanoma recurrence: a case report and review of the literature. Medical Oncology. 29(3). 2018–2020. 2 indexed citations
6.
Jury, Elizabeth C., Fabian Flores‐Borja, Mark Lazarus, et al.. (2009). Abnormal CTLA‐4 function in T cells from patients with systemic lupus erythematosus. European Journal of Immunology. 40(2). 569–578. 46 indexed citations
7.
Turner, David M., Denise Williams, David Sankaran, et al.. (1997). AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN‐10 GENE PROMOTER. European Journal of Immunogenetics. 24(1). 1–8. 1483 indexed citations breakdown →
8.
Lazarus, Mark, Ali H. Hajeer, David M. Turner, et al.. (1997). Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus.. PubMed. 24(12). 2314–7. 204 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026